217 related articles for article (PubMed ID: 26146842)
21. New paradigm of an old target: an update on structural biology and current progress in drug design towards plasmepsin II.
Dan N; Bhakat S
Eur J Med Chem; 2015 May; 95():324-48. PubMed ID: 25827401
[TBL] [Abstract][Full Text] [Related]
22. Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.
Hodder AN; Sleebs BE; Czabotar PE; Gazdik M; Xu Y; O'Neill MT; Lopaticki S; Nebl T; Triglia T; Smith BJ; Lowes K; Boddey JA; Cowman AF
Nat Struct Mol Biol; 2015 Aug; 22(8):590-6. PubMed ID: 26214367
[TBL] [Abstract][Full Text] [Related]
23. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum.
Asojo OA; Gulnik SV; Afonina E; Yu B; Ellman JA; Haque TS; Silva AM
J Mol Biol; 2003 Mar; 327(1):173-81. PubMed ID: 12614616
[TBL] [Abstract][Full Text] [Related]
24. Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors.
Huizing AP; Mondal M; Hirsch AK
J Med Chem; 2015 Jul; 58(13):5151-63. PubMed ID: 25719272
[TBL] [Abstract][Full Text] [Related]
25. Activation mechanism of plasmepsins, pepsin-like aspartic proteases from Plasmodium, follows a unique trans-activation pathway.
Rathore I; Mishra V; Patel C; Xiao H; Gustchina A; Wlodawer A; Yada RY; Bhaumik P
FEBS J; 2021 Jan; 288(2):678-698. PubMed ID: 32385863
[TBL] [Abstract][Full Text] [Related]
26. Sequence homology and structural analysis of plasmepsin 4 isolated from Indian Plasmodium vivax isolates.
Rawat M; Vijay S; Gupta Y; Dixit R; Tiwari PK; Sharma A
Infect Genet Evol; 2011 Jul; 11(5):924-33. PubMed ID: 21382523
[TBL] [Abstract][Full Text] [Related]
27. Structural insights into the activation of P. vivax plasmepsin.
Bernstein NK; Cherney MM; Yowell CA; Dame JB; James MN
J Mol Biol; 2003 Jun; 329(3):505-24. PubMed ID: 12767832
[TBL] [Abstract][Full Text] [Related]
28. Malaria parasite plasmepsins: More than just plain old degradative pepsins.
Nasamu AS; Polino AJ; Istvan ES; Goldberg DE
J Biol Chem; 2020 Jun; 295(25):8425-8441. PubMed ID: 32366462
[TBL] [Abstract][Full Text] [Related]
29. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
Bobrovs R; Jaudzems K; Jirgensons A
J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
[TBL] [Abstract][Full Text] [Related]
30. Egress and invasion machinery of malaria: an in-depth look into the structural and functional features of the flap dynamics of plasmepsin IX and X.
Munsamy G; Ramharack P; Soliman MES
RSC Adv; 2018 Jun; 8(39):21829-21840. PubMed ID: 35541758
[TBL] [Abstract][Full Text] [Related]
31. Recombinant plasmepsin 1 from the human malaria parasite plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis.
Liu P; Marzahn MR; Robbins AH; Gutiérrez-de-Terán H; Rodríguez D; McClung SH; Stevens SM; Yowell CA; Dame JB; McKenna R; Dunn BM
Biochemistry; 2009 May; 48(19):4086-99. PubMed ID: 19271776
[TBL] [Abstract][Full Text] [Related]
32. Sequence, Structural Analysis and Metrics to Define the Unique Dynamic Features of the Flap Regions Among Aspartic Proteases.
McGillewie L; Ramesh M; Soliman ME
Protein J; 2017 Oct; 36(5):385-396. PubMed ID: 28762197
[TBL] [Abstract][Full Text] [Related]
33. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
34. Modeling and resistant alleles explain the selectivity of antimalarial compound 49c towards apicomplexan aspartyl proteases.
Mukherjee B; Tessaro F; Vahokoski J; Kursula I; Marq JB; Scapozza L; Soldati-Favre D
EMBO J; 2018 Apr; 37(7):. PubMed ID: 29519896
[No Abstract] [Full Text] [Related]
35. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
36. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine.
Banerjee R; Liu J; Beatty W; Pelosof L; Klemba M; Goldberg DE
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):990-5. PubMed ID: 11782538
[TBL] [Abstract][Full Text] [Related]
37. Structural and active site analysis of plasmepsins of Plasmodium falciparum: potential anti-malarial targets.
Bhargavi R; Sastry GM; Murty US; Sastry GN
Int J Biol Macromol; 2005 Oct; 37(1-2):73-84. PubMed ID: 16242183
[TBL] [Abstract][Full Text] [Related]
38. Prodomain processing of recombinant plasmepsin II and IV, the aspartic proteases of Plasmodium falciparum, is auto- and trans-catalytic.
Kim YM; Lee MH; Piao TG; Lee JW; Kim JH; Lee S; Choi KM; Jiang JH; Kim TU; Park H
J Biochem; 2006 Feb; 139(2):189-95. PubMed ID: 16452306
[TBL] [Abstract][Full Text] [Related]
39. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from plasmodium falciparum.
Bernstein NK; Cherney MM; Loetscher H; Ridley RG; James MN
Nat Struct Biol; 1999 Jan; 6(1):32-7. PubMed ID: 9886289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
